Pay in 4 interest-free payments of $6.24 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
These results established the potential of this new hormone as a therapy for diabetes, but a key problem persisted
A total of 3286 patients had taken a GLP-1 RA and 1692 had taken an SGLT2i at some point in time
Beyond glycemic control, Semaglutide has demonstrated remarkable efficacy in promoting weight loss
Safety monitoring for GLP-1 therapy itself includes: Assessment for gastrointestinal adverse effects, which are common but usually transient Monitoring for signs of pancreatitis (severe, persistent abdominal pain) Vigilance for symptoms suggesting thyroid masses (neck lump, difficulty swallowing, persistent hoarseness) Regular review of glycaemic control in diabetic patients Blood pressure and cardiovascular risk factor assessment Monitoring for gallbladder disease (right upper abdominal pain, fever, jaundice) Eye examinations for people with diabetes, particularly those with pre-existing diabetic retinopathy Renal function checks, especially if experiencing severe gastrointestinal symptoms that could lead to dehydration If you have diabetes and take insulin or sulfonylureas, your doctor may reduce these doses when starting GLP-1 therapy to prevent hypoglycaemia
